Lindsey Marie Hartley Sells 14,812 Shares of AxoGen (NASDAQ:AXGN) Stock

by · The Markets Daily

AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) CFO Lindsey Marie Hartley sold 14,812 shares of AxoGen stock in a transaction on Monday, December 15th. The stock was sold at an average price of $29.86, for a total value of $442,286.32. Following the completion of the sale, the chief financial officer directly owned 31,376 shares of the company’s stock, valued at approximately $936,887.36. The trade was a 32.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Lindsey Marie Hartley also recently made the following trade(s):

  • On Monday, December 8th, Lindsey Marie Hartley sold 14,387 shares of AxoGen stock. The shares were sold at an average price of $31.56, for a total transaction of $454,053.72.

AxoGen Trading Up 1.0%

NASDAQ:AXGN opened at $31.70 on Friday. AxoGen, Inc. has a one year low of $9.22 and a one year high of $34.24. The business has a fifty day moving average price of $24.39 and a 200-day moving average price of $17.45. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -634.00 and a beta of 1.06. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.09 and a quick ratio of 2.64.

AxoGen (NASDAQ:AXGN – Get Free Report) last released its earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. The company had revenue of $60.08 million during the quarter, compared to analyst estimates of $56.90 million. AxoGen had a negative net margin of 0.98% and a negative return on equity of 1.90%. Sell-side analysts forecast that AxoGen, Inc. will post -0.29 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Jefferies Financial Group upped their target price on shares of AxoGen from $29.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Mizuho assumed coverage on AxoGen in a research report on Monday, December 1st. They set an “outperform” rating and a $40.00 price objective on the stock. Raymond James Financial reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of AxoGen in a research note on Thursday, December 4th. JMP Securities set a $34.00 target price on AxoGen in a research report on Thursday, October 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of AxoGen in a research report on Monday. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, AxoGen has an average rating of “Moderate Buy” and a consensus price target of $35.56.

View Our Latest Stock Analysis on AXGN

Hedge Funds Weigh In On AxoGen

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in AxoGen by 4.6% in the first quarter. Vanguard Group Inc. now owns 2,538,607 shares of the medical equipment provider’s stock worth $46,964,000 after purchasing an additional 112,679 shares in the last quarter. Swiss National Bank purchased a new position in shares of AxoGen in the 1st quarter worth approximately $1,498,000. Invesco Ltd. raised its stake in shares of AxoGen by 2,124.5% during the 1st quarter. Invesco Ltd. now owns 382,429 shares of the medical equipment provider’s stock worth $7,075,000 after acquiring an additional 365,237 shares in the last quarter. Nuveen LLC purchased a new stake in AxoGen during the first quarter valued at approximately $5,668,000. Finally, Algert Global LLC boosted its stake in AxoGen by 101.1% in the first quarter. Algert Global LLC now owns 28,520 shares of the medical equipment provider’s stock valued at $528,000 after acquiring an additional 14,340 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors.

About AxoGen

(Get Free Report)

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

See Also